• 2172 Citations
19992024
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Dr. Ma' clinical and research interests are focused on chronic lymphoid malignancies,including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

Certifications and Licenses

Medical Oncology
Hematology
Internal Medicine

Training Experience

2005Residency, Resurrection Hospitals
2008Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

PhD, Northwestern University Feinberg School of Medicine

… → 2000

MD, Beijing Medical University

… → 1994

Research interests

  • Biologic Therapies
  • Blood Cancer (leukemia and lymphomas)
  • Chronic Lymphocytic Leukemia
  • Hematology
  • Non-Hodgkin's Lymphoma
  • Oncology

Fingerprint Dive into the research topics where Shuo Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Dyneins Medicine & Life Sciences
Dictyostelium Medicine & Life Sciences
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Signal Transduction Medicine & Life Sciences
Leukocytes Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2007 2024

Research Output 1999 2019

4 Citations (Scopus)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., Malek, S. & 9 others, Mato, A., Mosse, C., Neppalli, V. T., Shadman, M., Siddiqi, T., Stephens, D., Wagner, N., Dwyer, M. A. & Sundar, H., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 1, p. 12-20 9 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Lymphoma
Guidelines
4 Citations (Scopus)

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., Hallek, M., Byrd, J. C., Humphrey, K., Zhou, L., Chyla, B., Nielsen, J., Potluri, J., Kim, S. Y., Verdugo, M., Stilgenbauer, S., Wierda, W. G. & Seymour, J. F., Jul 11 2019, In : Blood. 134, 2, p. 111-122 12 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Residual Neoplasm
Chromosomes
Refractory materials
Blood
5 Citations (Scopus)

Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia

Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., Ma, S., Tausch, E., Cramer, P., Huang, J. & 4 others, Mitra, S., Hallek, M., O’Brien, S. M. & Stilgenbauer, S., Jan 1 2019, In : Journal of Clinical Oncology. 37, 16, p. 1391-1402 12 p.

Research output: Contribution to journalArticle

Open Access
B-Cell Chronic Lymphocytic Leukemia
Placebos
Disease-Free Survival
Safety
idelalisib
1 Citation (Scopus)
Atrial Fibrillation
B-Cell Chronic Lymphocytic Leukemia
Electrocardiography
Therapeutics
Heart Diseases
B-Cell Chronic Lymphocytic Leukemia
Morbidity
Drug Therapy
Mortality